Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, Schaapveld M. Neppelenbroek SIM, et al. Among authors: plattel wj. J Clin Oncol. 2024 Jun 1;42(16):1903-1913. doi: 10.1200/JCO.23.01386. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38359378
Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015.
Reedijk AMJ, Zijtregtop EAM, Coebergh JWW, Meyer-Wentrup FAG, Hebeda KM, Zwaan CM, Janssens GOR, Pieters R, Plattel WJ, Dinmohamed AG, Zijlstra JM, Kremer LCM, Lugtenburg PJ, Beishuizen A, Karim-Kos HE. Reedijk AMJ, et al. Among authors: plattel wj. Br J Haematol. 2020 Jun;189(6):1093-1106. doi: 10.1111/bjh.16491. Epub 2020 Feb 6. Br J Haematol. 2020. PMID: 32030738 Free PMC article. Clinical Trial.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: plattel wj. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen RWM, Zijlstra JM, Beijert M, Nijziel MR, Verschueren KMS, Kremer LCM, van Eggermond AM, Lugtenburg PJ, Krol ADG, Roesink JM, Plattel WJ, van Spronsen DJ, van Imhoff GW, de Boer JP, Aleman BMP, van Leeuwen FE. de Vries S, et al. Among authors: plattel wj. J Natl Cancer Inst. 2021 Jun 1;113(6):760-769. doi: 10.1093/jnci/djaa194. J Natl Cancer Inst. 2021. PMID: 33351090 Free PMC article.
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
Brink M, Kahle XU, Vermaat JSP, Zijlstra JM, Chamuleau M, Kersten MJ, Durmaz M, Plattel WJ, Lugtenburg PJ, Stevens W, Mous R, de Vries EGE, van der Poel MWM, Panday PVN, Huls G, van Meerten T, Nijland M. Brink M, et al. Among authors: plattel wj. Blood Adv. 2021 Aug 10;5(15):2958-2964. doi: 10.1182/bloodadvances.2021004295. Blood Adv. 2021. PMID: 34338755 Free PMC article.
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Meeuwes FO, Brink M, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, Böhmer L, Woei-A-Jin S, Visser O, Oostvogels R, Jansen PM, Diepstra A, Snijders TJF, Plattel WJ, Huls GA, Vermaat JSP, Nijland M. Meeuwes FO, et al. Among authors: plattel wj. Eur J Cancer. 2022 Nov;176:100-109. doi: 10.1016/j.ejca.2022.09.008. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36208568 Free article.
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
Driessen J, Kersten MJ, Visser L, van den Berg A, Tonino SH, Zijlstra JM, Lugtenburg PJ, Morschhauser F, Hutchings M, Amorim S, Gastinne T, Nijland M, Zwezerijnen GJC, Boellaard R, de Vet HCW, Arens AIJ, Valkema R, Liu RDK, Drees EEE, de Jong D, Plattel WJ, Diepstra A; HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC). Driessen J, et al. Among authors: plattel wj. Leukemia. 2022 Dec;36(12):2853-2862. doi: 10.1038/s41375-022-01717-8. Epub 2022 Oct 14. Leukemia. 2022. PMID: 36241696
Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials.
Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Juul SJ, et al. Among authors: plattel wj. J Cancer Surviv. 2024 Jun;18(3):727-738. doi: 10.1007/s11764-022-01305-w. Epub 2022 Nov 28. J Cancer Surviv. 2024. PMID: 36441393
35 results